ストックスクリーナーアプリを入手
887.73
1.11%
-9.275
前日終値:
$897.00
開ける：
$896
24時間の取引高:
1.44M
Relative Volume:
0.49
時価総額：
$793.15B
収益：
$65.18B
当期純損益:
$20.64B
株価収益率:
39.30
EPS:
22.5894
ネットキャッシュフロー:
$5.96B
1週間 パフォーマンス:
-2.17%
1か月 パフォーマンス:
-15.68%
6か月 パフォーマンス:
+22.43%
1年 パフォーマンス:
+7.95%
1日の値動き範囲:
$885.50
$900.83
1週間の範囲:
$885.50
$926.77
52週間の値動き範囲:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
887.83 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
241.45 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
211.90 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
120.33 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
189.83 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Judge Advances Lilly Suit Over Online Platforms’ Mounjaro Copies - Bloomberg Law News
Eli Lilly stock price forecast: bears dominate as LLY consolidates near 200-day support - Traders Union
Clark Foundation, Lilly to partner on new downtown basketball court - Indiana Economic Digest
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target By Investing.com - Investing.com India
Jefferies reiterates Buy on Eli Lilly stock, $1,300 target - Investing.com
Lilly’s Ebglyss shows four-year efficacy in eczema study - Investing.com
Erste Group Bank Raises Eli Lilly's FY2027 Earnings Forecast - National Today
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis - prnewswire.com
AI Models Split on Eli Lilly: Strong Fundamentals, Premium Valuation - TipRanks
Pensionfund Sabic Buys $1.83M Stake in Eli Lilly - National Today
Pensionfund Sabic Makes New Investment in Eli Lilly and Company - National Today
Institutional Investors Are Selling One of Wall Street's Premier Trillion-Dollar Club Members (No, Not Nvidia!) - The Motley Fool
Bath Savings Trust Co Boosts Stake in Eli Lilly - National Today
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares - stocktitan.net
Why is Eli Lilly stock down today? - Traders Union
The Bull Case For Eli Lilly (LLY) Could Change Following Retatrutide Milestone And Governance ShiftLearn Why - simplywall.st
Eli Lilly stock price forecast: consolidation after recovery as LLY holds above long-term support - Traders Union
Eli Lilly's Sustainability in Pharmaceuticals Strategy - Sustainability Magazine
Assenagon Asset Management S.A. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY) - MarketBeat
Buy Eli Lilly Stock (LLY) as Employers Move to Cover Obesity Drugs, Says Morgan Stanley - TipRanks
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer? - Insider Monkey
Assessing Eli Lilly (LLY) Valuation After The Recent Share Price Pullback - simplywall.st
Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com
AI Models Split on Eli Lilly: Strong Growth vs. Premium Valuation - TipRanks
Spartan Planning & Wealth Management Buys Shares of 1,556 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by Dynamic Advisor Solutions LLC - MarketBeat
Biocon To Benefit After Eli Lilly Joins Novo Nordisk To Exit European Insulins Market - NDTV Profit
INNOVENT BIO-Eli Lilly Strategic Collaboration Deal Takes Effect; Rumored Acquisition Intent Not True - AASTOCKS.com
Eli Lilly to phase out select insulin products across Europe by 2027 - MSN
Workforce was region’s secret weapon in winning Eli Lilly | Opinion - PennLive.com
Martin Shkreli Says Silicon Valley's Hottest Health Obsession Is A 'Delusion' - Benzinga
Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study - TipRanks
Barclays Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls - TipRanks
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance Singapore
Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 - Benzinga
Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order - Fierce Pharma
Eli Lilly (NYSE:LLY) Sees Institutional Activity in Russell 1000 - Kalkine Media
Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform - Insider Monkey
Gradient Investments LLC Buys 19,634 Shares of Eli Lilly and Company $LLY - MarketBeat
Hutchens & Kramer Investment Management Group LLC Sells 3,715 Shares of Eli Lilly and Company $LLY - MarketBeat
Grove Bank & Trust Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Decreased by Sarasin & Partners LLP - MarketBeat
Nordea Investment Management AB Raises Stock Position in Eli Lilly and Company $LLY - MarketBeat
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,350 - Moomoo
Eli Lilly Stock: Analysts See 35% Upside, Driven by GLP-1 Demand and Q4 2025 ResultsNews and Statistics - IndexBox
What's going on with Eli Lilly on Monday? - MSN
Eli Lilly's diabetes drug cuts weight by 17% in trial - qz.com
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
0.58%
大文字化:
|
ボリューム (24 時間):